An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer's, new research shows.

Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

Kisunla is a 0nce-a-month, 30-minute infusion that is shown to slow the progression of the disease by 37 percent and reduce Alzheimer's-causing plaques by 84 percent.